Q1 Earnings Forecast for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2025 earnings estimates for CG Oncology in a research note issued on Monday, March 31st. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.58) for the quarter, down from their prior estimate of ($0.46). HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology's Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.44) EPS, FY2026 earnings at ($2.30) EPS, FY2027 earnings at ($1.81) EPS and FY2028 earnings at ($0.15) EPS.

Other equities analysts also recently issued reports about the stock. Morgan Stanley restated an "overweight" rating and set a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. TD Cowen started coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, CG Oncology has an average rating of "Buy" and a consensus price target of $63.88.

CG Oncology Trading Down 0.8 %

Shares of NASDAQ:CGON traded down $0.14 during trading on Thursday, hitting $16.78. 690,896 shares of the company were exchanged, compared to its average volume of 683,758. CG Oncology has a fifty-two week low of $15.71 and a fifty-two week high of $46.99. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -11.80 and a beta of 1.24. The firm has a fifty day moving average price of $26.72 and a two-hundred day moving average price of $31.10.

Remove Ads

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.11 million.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Institutional Trading of CG Oncology

Hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in CG Oncology during the 4th quarter worth $41,000. GAMMA Investing LLC grew its stake in shares of CG Oncology by 1,051.0% in the first quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock valued at $56,000 after acquiring an additional 2,102 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in CG Oncology during the fourth quarter worth about $68,000. KLP Kapitalforvaltning AS acquired a new stake in CG Oncology in the 4th quarter worth about $100,000. Finally, Federated Hermes Inc. bought a new stake in CG Oncology in the 4th quarter valued at about $172,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.